{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T05:03:08Z","timestamp":1776747788501,"version":"3.51.2"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,4,4]],"date-time":"2014-04-04T00:00:00Z","timestamp":1396569600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1007\/s00417-014-2611-9","type":"journal-article","created":{"date-parts":[[2014,4,2]],"date-time":"2014-04-02T21:22:31Z","timestamp":1396473751000},"page":"811-816","source":"Crossref","is-referenced-by-count":26,"title":["Topical 0.03\u00a0% tacrolimus for subepithelial infiltrates secondary to adenoviral keratoconjunctivitis"],"prefix":"10.1007","volume":"252","author":[{"given":"Eliya","family":"Levinger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omer","family":"Trivizki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonathan","family":"Shachar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Levinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Verssano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,4,4]]},"reference":[{"key":"2611_CR1","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0161-6420(02)00992-2","volume":"109","author":"J Hillenkamp","year":"2002","unstructured":"Hillenkamp J, Reinhard T, Ross RS, B\u00f6hringer D, Cartsburg O, Roggendorf M, De Clercq E, Godehardt E, Sundmacher R (2002) The effects of cidofovir 1% with and without cyclosporin A 1% as a topical treatment of acute adenoviral keratoconjunctivitis: a controlled clinical pilot study. Ophthalmology 109:845\u2013850","journal-title":"Ophthalmology"},{"key":"2611_CR2","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1001\/archopht.116.7.900","volume":"116","author":"YJ Gordon","year":"1998","unstructured":"Gordon YJ, Araullo-Cruz T, Romanowski EG (1998) The effects of topical nonsteroidal anti-inflammatory drugs on adenoviral replication. Arch Ophthalmol 116:900\u2013905","journal-title":"Arch Ophthalmol"},{"key":"2611_CR3","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1001\/archopht.119.10.1487","volume":"119","author":"J Hillenkamp","year":"2001","unstructured":"Hillenkamp J, Reinhard T, Ross RS, B\u00f6hringer D, Cartsburg O, Roggendorf M, De Clercq E, Godehardt E, Sundmacher R (2001) Topical treatment of acute adenoviral keratoconjunctivitis with 0.2% cidofovir and 1% cyclosporine: a controlled clinical pilot study. Arch Ophthalmol 119:1487\u20131491","journal-title":"Arch Ophthalmol"},{"key":"2611_CR4","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1001\/archopht.1978.03910060465016","volume":"96","author":"OE Lund","year":"1978","unstructured":"Lund OE, Stefani FH (1978) Corneal histology after epidemic keratoconjunctivitis. Arch Ophthalmol 96:2085\u20132088","journal-title":"Arch Ophthalmol"},{"key":"2611_CR5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/ICO.0b013e318033bd25","volume":"27","author":"A Sahin","year":"2008","unstructured":"Sahin A, Bozkurt B, Irkec M (2008) Topical cyclosporine a in the treatment of superior limbic keratoconjunctivitis: a long-term follow-up. Cornea 27:193\u2013195","journal-title":"Cornea"},{"key":"2611_CR6","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1097\/ICO.0b013e31812dfab3","volume":"26","author":"AA Ozcan","year":"2007","unstructured":"Ozcan AA, Ersoz TR, Dulger E (2007) Management of severe allergic conjunctivitis with topical cyclosporin a 0.05% eyedrops. Cornea 26:1035\u20131038","journal-title":"Cornea"},{"key":"2611_CR7","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0181-5512(07)91357-1","volume":"30","author":"S Doan","year":"2007","unstructured":"Doan S, Gabison E, Abitbol O, Gatinel D, Chast F, Hoang-Xuan T (2007) Efficacy of topical 2% cyclosporine A as a steroid-sparing agent in steroid-dependent vernal keratoconjunctivitis. J Fr Ophtalmol 30:697\u2013701","journal-title":"J Fr Ophtalmol"},{"key":"2611_CR8","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.7164\/antibiotics.40.1249","volume":"40","author":"T Kino","year":"1987","unstructured":"Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M, Kohsaka M, Aoki H, Imanaka H (1987) FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot 40:1249\u20131255","journal-title":"J Antibiot"},{"key":"2611_CR9","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2174\/1871528111312010006","volume":"12","author":"R Gallego-Pinazo","year":"2013","unstructured":"Gallego-Pinazo R, Dolz-Marco R, Mart\u00ednez-Castillo S, Ar\u00e9valo JF, D\u00edaz-Llopis M (2013) Update on the principles and novel local and systemic therapies for the treatment of non-infectious uveitis. Inflamm Allergy Drug Targets 12:38\u201345","journal-title":"Inflamm Allergy Drug Targets"},{"key":"2611_CR10","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/ICO.0b013e3181606086","volume":"27","author":"JS Dhaliwal","year":"2008","unstructured":"Dhaliwal JS, Mason BF, Kaufman SC (2008) Long-term use of topical tacrolimus (FK506) in high-risk penetrating keratoplasty. Cornea 27:488\u2013493","journal-title":"Cornea"},{"key":"2611_CR11","first-page":"475","volume":"108","author":"B Meyer-R\u00fcsenberg","year":"2011","unstructured":"Meyer-R\u00fcsenberg B, Loderst\u00e4dt U, Richard G, Kaulfers P-M, Gesser C (2011) Epidemic keratoconjunctivitis: the current situation and recommendations for prevention and treatment. Dtsch Arztebl Int 108:475\u2013480","journal-title":"Dtsch Arztebl Int"},{"key":"2611_CR12","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S0161-6420(00)00177-9","volume":"107","author":"Y Shiuey","year":"2000","unstructured":"Shiuey Y, Ambati BK, Adamis AP (2000) A randomized, double-masked trial of topical ketorolac versus artificial tears for treatment of viral conjunctivitis. Ophthalmology 107:1512\u20131517","journal-title":"Ophthalmology"},{"key":"2611_CR13","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s12009-000-0085-3","volume":"32","author":"RP Kowalski","year":"2000","unstructured":"Kowalski RP, Foulks GN, Gordon YJ (2000) Comparison of treatment regimens for ocular infections: community vs academic practice. Ann Ophthalmol 32:295\u2013300","journal-title":"Ann Ophthalmol"},{"key":"2611_CR14","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/00003226-200204000-00010","volume":"21","author":"EG Romanowski","year":"2002","unstructured":"Romanowski EG, Yates KA, Gordon YJ (2002) Topical corticosteroids of limited potency promote adenovirus replication in the Ad5\/NZW rabbit ocular model. Cornea 21:289\u2013291","journal-title":"Cornea"},{"key":"2611_CR15","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ico.0000127481.23714.b6","volume":"24","author":"EG Romanowski","year":"2005","unstructured":"Romanowski EG, Pless P, Yates KA, Gordon YJ (2005) Topical cyclosporine A inhibits subepithelial immune infiltrates but also promotes viral shedding in experimental adenovirus models. Cornea 24:86\u201391","journal-title":"Cornea"},{"key":"2611_CR16","first-page":"181","volume":"12","author":"S Lucchina","year":"2009","unstructured":"Lucchina S, Parvex SL, Biegger P, Fusetti C (2009) FK-506 ointment: an effective adjuvant therapy to treat a dramatic case of pyoderma gangrenosum of unilateral hand. Chin J Traumatol 12:181\u2013183","journal-title":"Chin J Traumatol"},{"key":"2611_CR17","doi-asserted-by":"crossref","first-page":"96","DOI":"10.2165\/00063030-199708020-00003","volume":"8","author":"AI Lauerma","year":"1997","unstructured":"Lauerma AI, Granlund H, Reitamo S (1997) Use of the newer immunosuppressive agents in dermatology. BioDrugs 8:96\u2013106","journal-title":"BioDrugs"},{"key":"2611_CR18","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/MLG.0b013e31804b1aad","volume":"117","author":"PP Caffier","year":"2007","unstructured":"Caffier PP, Harth W, Mayelzadeh B, Haupt H, Sedlmaier B (2007) Tacrolimus: a new option in therapy-resistant chronic external otitis. Laryngoscope 117:1046\u20131052","journal-title":"Laryngoscope"},{"key":"2611_CR19","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1097\/ICO.0b013e318243f69d","volume":"31","author":"GD Kymionis","year":"2012","unstructured":"Kymionis GD, Kankariya VP, Kontadakis GA (2012) Tacrolimus ointment 0.03% for treatment of refractory childhood phlyctenular keratoconjunctivitis. Cornea 31:950\u2013952","journal-title":"Cornea"},{"key":"2611_CR20","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/02713680802149115","volume":"33","author":"L Attas-Fox","year":"2008","unstructured":"Attas-Fox L, Barkana Y, Iskhakov V, Rayvich S, Gerber Y, Morad Y, Avni I, Zadok D (2008) Topical tacrolimus 0.03% ointment for intractable allergic conjunctivitis: an open-label pilot study. Curr Eye Res 33:545\u2013549","journal-title":"Curr Eye Res"},{"key":"2611_CR21","unstructured":"MedLine Plus (2013) Tacrolimus TM Drug Insert. National Institutes of Health (nlm.nih.gov)"},{"key":"2611_CR22","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2332\/allergolint.11-OA-0349","volume":"61","author":"N Ebihara","year":"2012","unstructured":"Ebihara N, Ohashi Y, Fujishima H, Fukushima A, Nakagawa Y, Namba K, Okamoto S, Shoji J, Takamura E, Uchio E, Miyazaki D (2012) Blood level of tacrolimus in patients with severe allergic conjunctivitis treated by 0.1% tacrolimus ophthalmic suspension. Allergol Int 61:275\u2013282","journal-title":"Allergol Int"},{"key":"2611_CR23","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1089\/jop.2009.0087","volume":"26","author":"Y Ohashi","year":"2010","unstructured":"Ohashi Y, Ebihara N, Fujishima H, Fukushima A, Kumagai N, Nakagawa Y, Namba K, Okamoto S, Shoji J, Takamura E, Hayashi K (2010) A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis. J Ocul Pharmacol Ther 26:165\u2013174","journal-title":"J Ocul Pharmacol Ther"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-014-2611-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-014-2611-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-014-2611-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T15:40:40Z","timestamp":1559058040000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-014-2611-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,4]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["2611"],"URL":"https:\/\/doi.org\/10.1007\/s00417-014-2611-9","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,4]]}}}